当前位置: X-MOL 学术Mol. Cancer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mutations in Noncoding Cis-Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer
Molecular Cancer Research ( IF 4.1 ) Pub Date : 2022-01-01 , DOI: 10.1158/1541-7786.mcr-21-0471
Samah El Ghamrasni 1 , Rene Quevedo 1, 2 , James Hawley 1, 2 , Parisa Mazrooei 1, 2, 3 , Youstina Hanna 1 , Iulia Cirlan 1 , Helen Zhu 1, 2, 4, 5 , Jeff P Bruce 1 , Leslie E Oldfield 1 , S Y Cindy Yang 1, 2 , Paul Guilhamon 6, 7 , Jüri Reimand 2, 5, 8 , Dave W Cescon 1 , Susan J Done 1, 2, 9 , Mathieu Lupien 1, 2, 5 , Trevor J Pugh 1, 2, 5
Affiliation  

Whole-genome sequencing of primary breast tumors enabled the identification of cancer driver genes and noncoding cancer driver plexuses from somatic mutations. However, differentiating driver from passenger events among noncoding genetic variants remains a challenge. Herein, we reveal cancer-driver cis -regulatory elements linked to transcription factors previously shown to be involved in development of luminal breast cancers by defining a tumor-enriched catalogue of approximately 100,000 unique cis -regulatory elements from 26 primary luminal estrogen receptor (ER)+ progesterone receptor (PR)+ breast tumors. Integrating this catalog with somatic mutations from 350 publicly available breast tumor whole genomes, we uncovered cancer driver cistromes, defined as the sum of binding sites for a transcription factor, for ten transcription factors in luminal breast cancer such as FOXA1 and ER, nine of which are essential for growth in breast cancer with four exclusive to the luminal subtype. Collectively, we present a strategy to find cancer driver cistromes relying on quantifying the enrichment of noncoding mutations over cis -regulatory elements concatenated into a functional unit. Implications: Mapping the accessible chromatin of luminal breast cancer led to discovery of an accumulation of mutations within cistromes of transcription factors essential to luminal breast cancer. This demonstrates coopting of regulatory networks to drive cancer and provides a framework to derive insight into the noncoding space of cancer.

中文翻译:

非编码顺式调控元件的突变揭示了管腔乳腺癌中的癌症驱动基因

原发性乳腺肿瘤的全基因组测序能够从体细胞突变中识别癌症驱动基因和非编码癌症驱动丛。然而,在非编码遗传变异中区分驾驶员事件和乘客事件仍然是一个挑战。在此,我们通过定义一个包含来自 26 个主要管腔雌激素受体 (ER) 的大约 100,000 个独特顺式调节元件的富含肿瘤的目录,揭示了与先前显示参与管腔乳腺癌发展的转录因子相关的癌症驱动顺式调节元件+ 孕酮受体 (PR)+ 乳腺肿瘤。将此目录与来自 350 个公开可用的乳腺肿瘤全基因组的体细胞突变相结合,我们发现了癌症驱动因子 cistromes,定义为转录因子结合位点的总和,管腔型乳腺癌中的 10 个转录因子,如 FOXA1 和 ER,其中 9 个对于乳腺癌的生长是必不可少的,其中 4 个是管腔型乳腺癌所独有的。总的来说,我们提出了一种寻找癌症驱动基因的策略,该策略依赖于量化非编码突变在顺式调控元件上的富集,这些元件串联成一个功能单元。意义:绘制 luminal 乳腺癌的可及染色质图导致发现 luminal 乳腺癌必需的转录因子的 cistromes 内突变的积累。这证明了监管网络的合作会驱动癌症,并提供了一个框架来深入了解癌症的非编码空间。总的来说,我们提出了一种寻找癌症驱动基因的策略,该策略依赖于量化非编码突变在顺式调控元件上的富集,这些元件串联成一个功能单元。意义:绘制 luminal 乳腺癌的可及染色质图导致发现 luminal 乳腺癌必需的转录因子的 cistromes 内突变的积累。这证明了监管网络的合作会驱动癌症,并提供了一个框架来深入了解癌症的非编码空间。总的来说,我们提出了一种寻找癌症驱动基因的策略,该策略依赖于量化非编码突变在顺式调控元件上的富集,这些元件串联成一个功能单元。意义:绘制 luminal 乳腺癌的可及染色质图导致发现 luminal 乳腺癌必需的转录因子的 cistromes 内突变的积累。这证明了监管网络的合作会驱动癌症,并提供了一个框架来深入了解癌症的非编码空间。绘制 luminal 乳腺癌的可及染色质图导致发现了 luminal 乳腺癌必需的转录因子的 cistromes 内突变的积累。这证明了监管网络的合作会驱动癌症,并提供了一个框架来深入了解癌症的非编码空间。绘制 luminal 乳腺癌的可及染色质图导致发现了 luminal 乳腺癌必需的转录因子的 cistromes 内突变的积累。这证明了监管网络的合作会驱动癌症,并提供了一个框架来深入了解癌症的非编码空间。
更新日期:2022-01-05
down
wechat
bug